|
1.
|
|
13 p, 828.8 KB |
Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions
/
Villatoro, Sergi (Grup Quirónsalud (Barcelona, Catalunya)) ;
Mayo-de-las-Casas, Clara (Grup Quirónsalud (Barcelona, Catalunya)) ;
Jordana-Ariza, Núria (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viteri-Ramírez, Santiago (Grup Quirónsalud (Barcelona, Catalunya)) ;
Garzón-Ibañez, Mónica (Grup Quirónsalud (Barcelona, Catalunya)) ;
Moya-Horno, Irene (Hospital General de Catalunya) ;
García-Peláez, Beatrtiz (Grup Quirónsalud (Barcelona, Catalunya)) ;
González-Cao, María (Grup Quirónsalud (Barcelona, Catalunya)) ;
Malapelle, Umberto (University of Naples Federico II) ;
Balada-Bel, Ariadna (Grup Quirónsalud (Barcelona, Catalunya)) ;
Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ;
Campos, Raquel (Grup Quirónsalud (Barcelona, Catalunya)) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Blanco, Remei (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Blasco, Ana (Hospital General Universitari de València) ;
Catalán, María J. (Grup Quirónsalud (Barcelona, Catalunya)) ;
González, Xavier (Hospital General de Catalunya) ;
Troncone, Giancarlo (University of Naples Federico II) ;
Karachaliou, Niki (Hospital del Sagrat Cor (Barcelona, Catalunya)) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Molina-Vila, Miguel Ángel (Grup Quirónsalud (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
Many advanced cases of cancer show central nervous system, pleural, or peritoneal involvement. In this study, we prospectively analyzed if cerebrospinal fluid (CSF), pleural effusion (PE), and/or ascites (ASC) can be used to detect driver mutations and guide treatment decisions. [...]
2019 -  10.1002/1878-0261.12574
Molecular Oncology, Vol. 13 Núm. 12 (january 2019) , p. 2633-2645
|
|
|
2.
|
|
14 p, 1.8 MB |
Usefulness of two independent DNA and rna tissue-based multiplex assays for the routine care of advanced NSCLC patients
/
Marin, Elba (Hospital Clínic i Provincial de Barcelona) ;
Teixidó, Cristina (Hospital Clínic i Provincial de Barcelona) ;
Carmona Rocha, Elena (Hospital Clínic i Provincial de Barcelona) ;
Reyes, Roxana (Hospital Clínic i Provincial de Barcelona) ;
Arcocha, Ainara (Hospital Clínic i Provincial de Barcelona) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Rodríguez-Mues, M Carmen (Hospital Clínic i Provincial de Barcelona) ;
Cabrera, C. (Instituto Oncologico Dr. Rosell) ;
Sánchez, Marcelo (Hospital Clínic i Provincial de Barcelona) ;
Vollmer, Ivana G. (Hospital Clínic i Provincial de Barcelona) ;
Castillo, S. (Hospital General de Granollers) ;
Muñoz, S. (Hospital General de Granollers) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez, Adela (Hospital Clínic i Provincial de Barcelona) ;
Garcia, Mireia (Hospital Clínic i Provincial de Barcelona) ;
Alos, Silvia (Hospital Clínic i Provincial de Barcelona) ;
Jares, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Martinez, Antonio (Hospital Clínic i Provincial de Barcelona) ;
Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ;
Molina-Vila, M.Á. (Quirón Dexeus University Hospital) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Personalized medicine is nowadays a paradigm in lung cancer management, offering important benefits to patients. This study aimed to test the feasibility and utility of embedding two multiplexed genomic platforms as the routine workup of advanced non-squamous non-small cell lung cancer (NSCLC) patients. [...]
2020 - 10.3390/cancers12051124
Cancers, Vol. 12 Núm. 5 (may 2020) , p. 1124
|
|
|
3.
|
|
10 p, 654.4 KB |
Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform
/
Giménez-Capitán, Ana (Grup Quirónsalud (Barcelona, Catalunya)) ;
Bracht, Jillian (Universitat Autònoma de Barcelona) ;
García Mosquera, Juan José (Grup Quirónsalud (Barcelona, Catalunya)) ;
Jordana-Ariza, Núria (Grup Quirónsalud (Barcelona, Catalunya)) ;
García, Beatriz (Grup Quirónsalud (Barcelona, Catalunya)) ;
Garzón Ibáñez, Mónica (Grup Quirónsalud (Barcelona, Catalunya)) ;
Mayo-De-Las-Casas, Clara (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viteri, Santiago (Grup Quirónsalud (Barcelona, Catalunya)) ;
Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ;
Aguilar-Hernández, Andrés (Grup Quirónsalud (Barcelona, Catalunya)) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Johnson, Eric (NanoString Technologies) ;
Huang, Chun-Ying (NanoString Technologies) ;
Gerlach, Jay L. (NanoString Technologies) ;
Warren, Sarah (NanoString Technologies) ;
Beechem, Joseph M. (NanoString Technologies) ;
Teixidó, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ;
Molina-Vila, Miguel Ángel. (Grup Quirónsalud (Barcelona, Catalunya))
BACKGROUND: With the advent of precision oncology, liquid biopsies are quickly gaining acceptance in the clinical setting. However, in some cases, the amount of DNA isolated is insufficient for Next-Generation Sequencing (NGS) analysis. [...]
2021 - 10.1093/clinchem/hvaa248
Clinical Chemistry, Vol. 67 Núm. 3 (january 2021) , p. 554-563
|
|
|
4.
|
|
12 p, 339.3 KB |
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC : Results From the Phase 3 TAHOE Study
/
Blackhall, Fiona (Department of Medical Oncology. The Christie National Health Service (NHS) Foundation Trust) ;
Jao, K. (Department of Hematology and Oncology. Hopital du Sacre Coeur Montreal) ;
Greillier, L. (Multidisciplinary Oncology and Therapeutic Innovations Department. Centre de Recherche en Cancérologie de Marseille (CRCM). Centre National de la Recherche Scientifique (CNRS). Institut National de la Santé et de la Recherche Médicale (INSERM). Assistance Publique-Hopitaux de Marseille (APHM). Aix-Marseille University) ;
Cho, B.C. (Division of Medical Oncology. Department of Internal Medicine. Yonsei Cancer Center. Yonsei University College of Medicine) ;
Penkov, K. (Private Medical Institution Euromedservice) ;
Reguart, Noemi (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Nackaerts, K. (Department of Pulmonology and Respiratory Oncology. University Hospital Leuven. Katholieke Universiteit (KU) Leuven) ;
Syrigos, K. (Department of Medicine. National and Kapodistrian University of Athens) ;
Hansen, K. (Odense University Hospital (Dinamarca)) ;
Schuette, W. (2nd Medical Department. Krankenhaus Martha-Maria Halle-Doelau. Halle) ;
Cetnar, J. (Department of Medicine. Oregon Health & Science University) ;
Cappuzzo, F. (Department of Medical Oncology. Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)) ;
Okamoto, I. (Department of Medical Oncology. Kyushu University Hospital) ;
Erman, M. (Department of Medical Oncology. Cancer Institute. Hacettepe University) ;
Langer, S.W. (Rigshospitalet. University of Copenhagen) ;
Kato, T. (Department of Thoracic Oncology. Kanagawa Cancer Center) ;
Groen, H. (Department of Pulmonary Disease. University Medical Center Groningen. University of Groningen) ;
Sun, Z. (AbbVie. Inc.) ;
Luo, Y. (AbbVie. Inc.) ;
Tanwani, P. (AbbVie. Inc.) ;
Caffrey, L. (AbbVie. Inc.) ;
Komarnitsky, P. (AbbVie. Inc.) ;
Reinmuth, N. (Thoracic Oncology Department. Asklepios Fachkliniken München-Gauting)
Introduction: DLL3, an atypical Notch ligand, is expressed in SCLC tumors but is not detectable in normal adult tissues. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate containing a DLL3-targeting antibody tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. [...]
2021 - 10.1016/j.jtho.2021.02.009
Journal of Thoracic Oncology, Vol. 16 Núm. 9 (september 2021) , p. 1547-1558
|
|
|
5.
|
|
14 p, 2.2 MB |
Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer
/
Aguado, Cristina (Quirón Dexeus University Hospital) ;
Teixidó, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Román, Ruth (Quirón Dexeus University Hospital) ;
Reyes, Roxana (Hospital Clínic i Provincial de Barcelona) ;
Giménez-Capitán, Ana (Quirón Dexeus University Hospital) ;
Marin, Elba (Hospital Clínic i Provincial de Barcelona) ;
Cabrera, Carlos (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Castillo, Sergi (Hospital General de Granollers) ;
Muñoz, Silvia (Hospital General de Granollers) ;
Arcocha, Ainara (Hospital Clínic i Provincial de Barcelona) ;
López Vilaró, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Aldeguer, Erika (Quirón Dexeus University Hospital) ;
Rodríguez, Sonia (Quirón Dexeus University Hospital) ;
Moya, Irene (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viteri, Santiago (Quiron Salud Group) ;
Cardona Zorrilla, Andrés Felipe (Clínica del Country) ;
Palmero, Ramon (L'Hospitalet) ;
Sainz, Cristina (Centro de Investigación Biomédica en Red de Cáncer) ;
Mesa-Guzmán, Miguel (Universidad Pública de Navarra) ;
Lozano, Maria D. (Universidad Pública de Navarra) ;
Aguilar-Hernández, Andrés (Grup Quirónsalud (Barcelona, Catalunya)) ;
Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ;
González-Cao, María (Grup Quirónsalud (Barcelona, Catalunya)) ;
Gonzalvo, Elena (Hospital Clínic i Provincial de Barcelona) ;
Leenders, William P. J. (Radboud Institute for Molecular Life Sciences) ;
Rosell, Rafael (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Montuenga, Luis M. (Universidad Pública de Navarra) ;
Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ;
Molina-Vila, Miguel Ángel (Quirón Dexeus University Hospital) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona)
We studied MET alterations in 474 advanced non-small-cell lung cancer (NSCLC) patients by nCounter, an RNA-based technique. We identified 3% with MET Δex14 mRNA and 3. 5% with very-high MET mRNA expression, a surrogate of MET amplification. [...]
2020 - 10.1002/1878-0261.12861
Molecular Oncology, Vol. 15 (december 2020) , p. 350-363
|
|
|
6.
|
|
13 p, 2.1 MB |
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma : the ROSING Study
/
Conde, Esther (Hospital Universitario HM Sanchinarro (Madrid)) ;
Hernández, Susana (Hospital Universitario HM Sanchinarro (Madrid)) ;
Martinez, Rebeca (Hospital Universitario HM Sanchinarro (Madrid)) ;
Angulo, Bárbara (Hospital Universitario HM Sanchinarro (Madrid)) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Collazo-Lorduy, Ana (Hospital Universitario HM Sanchinarro (Madrid)) ;
Jimenez, Beatriz (Hospital Universitario HM Sanchinarro (Madrid)) ;
Muriel, Alfonso (Hospital Universitario Ramón y Cajal (Madrid)) ;
Mate Sanz, Jose Luís (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Aranda, Ignacio (Instituto de Investigación Sanitaria y Biomédica de Alicante) ;
Massuti, Bartomeu (Instituto de Investigación Sanitaria y Biomédica de Alicante) ;
Rojo, Federico (Centro de Investigación Biomédica en Red de Cáncer) ;
Dómine Gómez, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Sansano, Irene (Hospital Universitari Vall d'Hebron) ;
Garcia, Felip (Quironsalud Hospital) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Mancheño, Nuria (Hospital Universitari i Politècnic La Fe (València)) ;
Juan, Óscar (Hospital Universitari i Politècnic La Fe (València)) ;
Sanz, Julián (Hospital Clínico San Carlos (Madrid)) ;
Gonzalez-Larriba, José Luis (Hospital Clínico San Carlos (Madrid)) ;
Atienza-Cuevas, Lidia (Hospital Universitario Puerta del Mar (Cadis, Andalusia)) ;
Arriola-Arellano, Esperanza (Hospital Universitario Puerta del Mar (Cadis, Andalusia)) ;
Abdulkader, Ihab (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Garcia-Gonzalez, Jorge (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Camacho, Carmen (Insular Materno-Infantil University Hospital Complex) ;
Rodríguez-Abreu, Delvys (Insular Materno-Infantil University Hospital Complex) ;
Teixidó, Cristina (Hospital Clínic i Provincial de Barcelona) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ;
Gonzalez-Piñeiro, Ana (Hospital Álvaro Cunqueiro (Vigo)) ;
Lázaro, Martín (Hospital Álvaro Cunqueiro (Vigo)) ;
Lozano, María Dolores (Clínica Universidad de Navarra) ;
Gurpide, Alfonso (Clínica Universidad de Navarra) ;
Gómez-Román, Javier (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Lopez-Brea, M. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Pijuan, Lara (Hospital del Mar (Barcelona, Catalunya)) ;
Salido, Marta (Hospital del Mar (Barcelona, Catalunya)) ;
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
Company, Amparo (Hospital Clínic Universitari (València)) ;
Insa, Amelia (Hospital Clínic Universitari (València)) ;
Esteban-Rodriguez, Isabel (Hospital Universitario La Paz (Madrid)) ;
Saiz, Mónica (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Azkona, Eider (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Álvarez, Ramiro (Hospital Universitario Miguel Servet (Saragossa)) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Plaza, María Luz (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Aguiar de Sousa, Diana (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Enguita, Ana Belén (Hospital Universitario 12 de Octubre (Madrid)) ;
Benito, Amparo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid)) ;
Garrido, Pilar (Centro de Investigación Biomédica en Red de Cáncer) ;
Lopez-Rios, Fernando (Hospital Universitario HM Sanchinarro (Madrid)) ;
Universitat Autònoma de Barcelona
Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. [...]
2019 - 10.1016/j.jtho.2019.07.005
Journal of Thoracic Oncology, Vol. 14 Núm. 12 (december 2019) , p. 2120-2132
|
|
|
7.
|
|
15 p, 955.9 KB |
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
/
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Juan, Óscar (Hospital Universitari i Politècnic La Fe (València)) ;
Insa, Amelia (Hospital Clínic Universitari (València)) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ;
Trigo, J. M. (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ;
García García, Yolanda (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Guirado, M. (Hospital General Universitario de Elche) ;
Provencio, M. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Universitat Autònoma de Barcelona
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular knowledge; so, more options can be offered to patients with driver mutations. [...]
2018 - 10.1007/s12094-018-1978-1
Clinical & Translational Oncology, Vol. 21 (november 2018) , p. 3-17
|
|
|
8.
|
|
12 p, 1.4 MB |
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
/
Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Karachaliou, Niki (Instituto Oncológico Dr. Rosell, Institut Universitari Quirón-Dexeus) ;
Pilotto, Sara (Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona) ;
Codony-Servat, Jordi (Pangaea Biotech, Laboratory of Molecular Biology) ;
Cai, Xueting (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ;
Li, Xuefei (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ;
Drozdowskyj, Ana (Pivotal, Madrid) ;
Codony Servat, Carles (Pangaea Biotech, Laboratory of Molecular Biology) ;
Yang, Jie (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ;
Hu, Chunping (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ;
Cardona Zorrilla, Andrés Felipe (Clinica del Country, Bogotá) ;
Lopez Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Vergnenegre, Alain (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ;
Sanchez, Jose Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Marinis, Filippo de (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Passaro, Antonio (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Carcereny, Enric (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ;
Garcia Campelo, Charo (Hospital Universitario de la Princesa (Madrid)) ;
Teixidó, Cristina (Pangaea Biotech, Laboratory of Molecular Biology) ;
Sperduti, Isabella (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Rodriguez, Sonia (Pangaea Biotech, Laboratory of Molecular Biology) ;
Lavazzi, Chiara (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Verlicchi, Alberto (Hospital Clínic i Provincial de Barcelona) ;
Aguirre, Itziar de (Institut Germans Trias i Pujol) ;
Queralt, C (Institut Germans Trias i Pujol) ;
Wei, Jia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Estrada-Tejedor, Roger (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ;
Puig de la Bellacasa, Raimon (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol) ;
Jacobson, Kirstine (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ;
Ditzel, Henrik J. (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ;
Santarpia, Mariacarmela (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ;
Viteri, Santiago (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Molina, Miguel Angel (Pangaea Biotech, Laboratory of Molecular Biology) ;
Zhou, Caicun (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ;
Cao, Peng (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China) ;
Ma, Patrick C. (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ;
Bivona, Trever (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Background: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non- small cell lung cancer (NSCLC) is limited by adaptive activation of cell survival signals. [...]
2017
Journal of the National Cancer Institute, Vol. 109 (september 2017) , p. 1-12
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
